-
-
-
-
-
-
-
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
-
-
-
-
-
-
-
Xeris’ Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics
-
-
-
-
-
-
-
Xeris Pharmaceuticals Inc. (XERS) Granted FDA Approval for Recorlev to Treat Endogenous Hypercortisolemia in Adult Patients With Cushing's Syndrome
-
-
-
-
-
-
-
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
-
-
-
-
-
-
-
Xeris Pharmaceuticals Inc. (XERS) Phase 1 Levothyroxine Study Enrollment Completed
-
-
-
-
-
-
-
Xeris Pharmaceuticals Strengthens Its Patent Estate
-
-
-
-
-
-
-
Xeris Pharmaceuticals Inc. (XERS) Misses Q2 EPS by 11c
-
1,199,247 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


